HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Peptides & GLP-1. Browse all Peptides & GLP-1 education

Ask any single gene about your growth hormone axis response and you’ll get a single gene’s answer. Ask the full genetic system and you get something far more useful: a map of how your biology is actually configured — where the signals fire loudly and where they get dampened, where the architecture is built for power and where it’s built for endurance, where recovery runs fast and where it accumulates debt. The Precision Peptide Genetic Test delivers 15 Muscle Growth insights across 14 pathways, 49 peptides, and 150+ genetic insights — including the eight genes that together map the complete genetic architecture of growth hormone axis response.

The Growth Hormone Axis as a Genetic System

The growth hormone axis is not a single mechanism — it’s a cascading signal chain with multiple conversion steps, each governed by different genes. Understanding how that chain behaves in your body requires reading all of them, because a strong signal at one step can be attenuated at the next, and a weak signal at one step can be amplified downstream if the right architecture is present.

The eight genes the Precision Peptide Genetic Test analyzes within the growth hormone axis picture can be organized into four functional layers — each layer representing a different stage of the cascade from initial GH pulse to final hypertrophic adaptation:

Layer 1 — Signal Generation: How loudly does the GH pulse fire?

Layer 2 — Signal Translation: How completely does GH convert into anabolic messenger?

Layer 3 — Signal Reception: What does the anabolic signal land on?

Layer 4 — System Support: What amplifies, delivers, and recovers?

Layer 1 — Signal Generation: GHSR and GHR

The growth hormone axis begins in the pituitary, where somatotroph cells release GH in discrete pulses. Two genes govern the sensitivity of that release system:

GHSR — the ghrelin receptor — determines how sensitively pituitary somatotrophs respond to ghrelin-type stimulation. GHSR has constitutive activity, meaning it generates baseline GH pulsatility even without ligand bound. Variants in GHSR influence peak GH pulse amplitude and the resting GH tone between pulses. A lower-sensitivity GHSR genotype produces smaller, less frequent GH pulses at baseline — constraining the entire downstream cascade before IGF-1 is ever synthesized.

GHR — the growth hormone receptor — determines how sensitively peripheral tissues (particularly the liver) read the GH signal that GHSR helps generate. Variants in GHR affect receptor expression level and binding efficiency. A strong GH pulse from a high-sensitivity GHSR will produce a proportionally weaker IGF-1 output if GHR variants attenuate hepatic receptor signaling. Both genes must be read together to understand what the liver actually receives.

Layer 2 — Signal Translation: IGF-1 and the Anabolic Messenger

Once the liver reads the GH signal through GHR, it synthesizes and secretes IGF-1 — the primary anabolic messenger that drives muscle protein synthesis, satellite cell activation, and tissue repair. The efficiency of that translation is shaped by:

IGF1 variants — particularly the 192bp CA repeat polymorphism and associated SNPs — influence how much IGF-1 the liver produces per unit of GH stimulation. Individuals with genotypes associated with higher IGF-1 output operate with a stronger resting anabolic signal and a larger stimulus-driven response. Those with lower-output genotypes produce the same downstream machinery in response to equivalent GH stimulation, but at a reduced amplitude.

The Layer 2 net effect: even if Layer 1 generates a strong GH pulse, an attenuated IGF1 genotype will produce a proportionally modulated anabolic messenger output. And if Layer 1 is modest but IGF1 genotype is high-output, the liver may partially compensate. Reading GHSR, GHR, and IGF1 together reveals whether your axis has high gain, low gain, or a compensating configuration at the translation step.

Layer 3 — Signal Reception: Fiber Architecture and the Hypertrophy Ceiling

IGF-1 binds receptors on muscle cells and satellite cells, activating the PI3K/Akt/mTOR pathway for protein synthesis and the satellite cell proliferation cascade for structural repair. What that signal actually builds depends on two variables that Layers 1 and 2 cannot control:

ACTN3 (R577X) — the “sprint gene” — determines your fast-twitch versus slow-twitch fiber composition. Fast-twitch fibers hypertrophy more aggressively in response to IGF-1 signaling than slow-twitch fibers do. RR genotype individuals carry more fast-twitch fibers and tend to express visible hypertrophy more rapidly from equivalent anabolic signal strength. XX genotype individuals recover faster and tolerate higher volume but see a more modulated hypertrophy response per unit of anabolic signal.

MSTN (myostatin) — the hypertrophy ceiling gene — actively suppresses satellite cell proliferation and muscle protein accretion regardless of how strong the upstream anabolic signal is. MSTN genotype determines how tightly that brake is applied. A strong IGF-1 signal landing on a high-myostatin cellular environment produces a smaller hypertrophic outcome than the same signal landing on a low-myostatin environment. The Layer 1–2 signal strength only partially predicts outcome — Layer 3 reception architecture determines how much of that signal converts to mass.

Layer 4 — System Support: VDR, ACE, and IL-6

The three remaining genes don’t sit on the primary GH→IGF-1→muscle axis — they govern the environment in which that axis operates, the infrastructure through which signals are delivered, and the recovery architecture that determines how much productive training volume the system can accumulate:

VDR — the vitamin D receptor — amplifies the anabolic signal at the muscle fiber level by upregulating IGF-1 receptor expression. More IGF-1 receptors on muscle cell surfaces means greater sensitivity to the circulating IGF-1 that Layers 1 and 2 generate. VDR genotype is effectively a gain control on IGF-1 signaling sensitivity — an FF genotype individual and a ff genotype individual can receive identical circulating IGF-1 and produce meaningfully different receptor-level responses. VDR also influences calcium handling, satellite cell activation, and fiber type composition, creating additional compound interactions with Layer 3.

ACE — the I/D polymorphism — governs the vascular infrastructure through which IGF-1 physically reaches muscle tissue. DD genotype carriers produce more angiotensin II, which drives direct AT1R-mediated protein synthesis in muscle cells alongside IGF-1 signaling — a secondary anabolic signal that II genotype carriers lack. II genotype carriers compensate with superior bradykinin-driven vasodilation, which may enhance IGF-1 delivery to working muscle during and after training. ACE genotype doesn’t alter the signal — it shapes the delivery system and adds or removes a parallel anabolic route.

IL-6 — the recovery gene — determines how vigorously satellite cell activation and tissue repair proceed in the gap between training sessions. GG genotype carriers produce a larger IL-6 myokine pulse per session, generating a stronger satellite cell activation signal that compounds with the IGF-1-driven satellite cell response from Layers 1 and 2. But GG carriers also accumulate more per-session inflammatory load, narrowing the margin between productive stress and systemic overtraining. IL-6 genotype determines the training frequency ceiling that the entire system can sustain.

Reading the Full Panel Together

The compounding effects across all four layers are where genetic testing creates real clinical value. Consider the difference between two hypothetical profiles:

A person with high-sensitivity GHSR, high-output IGF1, RR ACTN3, low myostatin activity, FF VDR, DD ACE, and GG IL-6 genotype is operating with maximum gain at every layer — a strong signal, efficiently translated, landing on high-response fiber architecture with amplified reception, a direct secondary anabolic pathway, and a robust satellite cell activation signal per session. The main management challenge is recovery: that GG IL-6 genotype creates a higher per-session inflammatory burden that requires deliberate recovery management to prevent the strong signal from tipping into overtraining.

A person with moderate GHSR sensitivity, modest IGF1 output, XX ACTN3, higher myostatin activity, ff VDR, II ACE, and CC IL-6 genotype is working with modulated gain at multiple layers — but they recover faster, tolerate higher training frequency, and may accumulate equivalent hypertrophy over a longer window through volume rather than intensity. Their protocol looks different. Neither profile is better. Both are genetically coherent strategies for achieving the same goal through different biological routes.

This is the value proposition of test before you invest: genetics as a guide, not a guarantee, but a guide that materially changes the quality of the conversation with your healthcare provider. PlexusDx tells you about your biology. It does not tell you what to put in your body.

The Precision Peptide Genetic Test analyzes how your genes influence muscle growth pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to map all eight layers of your growth hormone axis genetic profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Genetics and Growth Hormone Axis Response

What genes determine growth hormone axis peptide response?

At least eight genes in the Precision Peptide Genetic Test’s 15 Muscle Growth insights influence GH axis response: GHSR (GH release trigger), GHR (receptor sensitivity), IGF1 (downstream mediator), ACTN3 (fiber architecture), MSTN (hypertrophy ceiling), VDR (anabolic amplifier), ACE (delivery infrastructure), and IL-6 (recovery and satellite cell activation). No single gene tells the full story.

Can genetic testing predict growth hormone axis peptide response?

Genetic testing does not predict response to any specific compound — that claim would exceed what the science supports. What the Precision Peptide Genetic Test delivers is a complete picture of your GH axis genetic architecture: 15 Muscle Growth insights that reveal biological starting points for growth hormone axis protocol discussions with your healthcare provider.

How many genes does the Precision Peptide Genetic Test analyze for muscle growth?

The Precision Peptide Genetic Test analyzes 15 Muscle Growth insights — including GHSR, GHR, IGF1, ACTN3, MSTN, VDR, ACE, and IL-6 — as part of a broader panel spanning 14 pathways, 49 peptides, 150+ genetic insights, 48 genes, and 57 SNPs analyzed on the Illumina Global Screening Array at CLIA-certified labs.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.